Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation

Histone deacetylase inhibitors (HDACIs) represent an intriguing class of pharmacologically active compounds. Currently, some HDACIs are FDA approved for cancer therapy and many others are in clinical trials, showing important clinical activities at well tolerated doses. HDACIs also interfere with th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oxid Med Cell Longev
Main Authors: Borriello, Adriana, Naviglio, Silvio, Bencivenga, Debora, Caldarelli, Ilaria, Tramontano, Annunziata, Speranza, Maria Carmela, Stampone, Emanuela, Sapio, Luigi, Negri, Aide, Oliva, Adriana, Sinisi, Antonio Agostino, Spina, Annamaria, Della Ragione, Fulvio
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi Publishing Corporation 2016
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670678/
https://ncbi.nlm.nih.gov/pubmed/26682002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2481865
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares